Climb Bio IncCLYM
▲ ポジティブ技術関連度
Pipeline progress and positive early clinical data for Budoprutug and CLYM116 drove 310% gain.
銘柄への影響 5
Biotech & Genomic Medicine
Climb Bio Inc
Eton Pharmaceuticals IncETON
▲ ポジティブ規制関連度
FDA approval of DESMODA and multiple commercial deals supported 128% gain.
Liquidia Technologies IncLQDA
▲ ポジティブ需要関連度
Launch and expanding adoption of Yutrepia fueled 249% surge.
UroGen Pharma LtdURGN
▲ ポジティブ規制関連度
FDA approval of Zusduri and strong revenue growth led to 280% climb.
Health Care
Tectonic Therapeutic, Inc.TECX
▲ ポジティブ技術関連度
Positive Phase 1b results for TX45 and initiation of multiple clinical trials drove 121% gain.